Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019 Agenda


Print Agenda

Monday, 9 September 2019

00:00

Inhibition of Exosome Secretion in Cancer Cells by an Antibiotic
Moon-Chang Baek, Director, Exosome Convergence Research Center (ECRC), Kyungpook National University School of Medicine, Korea South

Inhibitors of the secretion of cancer exosomes, which promote cancer progression and metastasis, may not only accelerate exosome biology research but also offer therapeutic benefits for cancer patients. We identify sulfisoxazole (SFX) as an inhibitor of small extracellular vesicles (sEV) secretion from breast cancer cells through interference with endothelin receptor A (ETA). SFX, an FDA-approved oral antibiotic, showed significant anti-tumor and anti-metastatic effects in mouse models of breast cancer xenografts, reduced the expression of proteins involved in biogenesis and secretion of sEV, and triggered co-localization of multivesicular endosomes with lysosomes for degradation. The important role of ETA, as a newly-identified target of SFX, is demonstrated by gain- and loss-of-function studies of ETA protein through a direct binding assay, pharmacological and genetic approaches. These findings may provide a foundation for sEV-targeted cancer therapies and the mechanistic studies on sEV biology.

00:00

Title to be Confirmed.
Kihwan Kwon, Professor, Ewha Womans University College of Medicine, Korea South

00:00

Sai Kiang LimKeynote Presentation

Title to be Confirmed.
Sai Kiang Lim, Research Director, Institute of Medical Biology, A*STAR, Singapore

00:00

The Effects of ASC-Exosome on Dermatitis
Yong Weon Yi, Head of Institute, ExoCoBio Exosome Institute, ExoCoBio Inc., Korea South

Exosome from human adipose tissue-derived mesenchymal stem cells (ASC-EXOSOME) was isolated from the serum-free conditioned media by sequential filtration and characterized as recommended by the International Society for Extracellular Vesicles (ISEV). Previously, we revealed that the ASC-EXOSOME alleviates the atopic dermatitis in an inflammatory murine model through down-regulation of multiple cytokine mRNA expression. As a subsequent study, we further analyzed the effects of ASC-EXOSOME on an alternative murine model of atopic dermatitis.  The effects of ASC-EXOSOME on the skin barrier function will be presented and discussed.

00:00

Yong Song GhoConference Chair

Title to be Confirmed.
Yong Song Gho, Professor, Pohang University Of Science And Technology South Korea, Korea South

00:00

Chulhee ChoiConference Chair

Title to be Confirmed.
Chulhee Choi, Professor and Chair, BioMedical Imaging Center, Korea Advanced Institute of Science and Technology (KAIST), President, ILIAS Biologics Incorporated, Korea South

00:00

Dominique PV de KleijnKeynote Presentation

Title to be Confirmed.
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

00:00

Sehyun ShinKeynote Presentation

Title to be Confirmed.
Sehyun Shin, Professor & Director, Nano-Biofluignostic Engineering Research Center, Korea University and Anam/Guro Hospital of Korea University, Korea South

00:00

Chwee Teck LimKeynote Presentation

Title to be Confirmed.
Chwee Teck Lim, NUS Society Chair Professor, Acting Director, Biomedical Institute for Global Health Research and Technology, National University of Singapore, Singapore

00:00

Hyo-Il JungKeynote Presentation

Title to be Confirmed.
Hyo-Il Jung, Professor, Yonsei University, Korea South

00:00

Yoon-Kyoung ChoKeynote Presentation

Title to be Confirmed.
Yoon-Kyoung Cho, Professor, Biomedical Engineering, Ulsan National Institute of Science & Technology; Group leader, IBS; FRSC, Fellow of Royal Society of Chemistry, Korea South

00:00

Jan LötvallKeynote Presentation

Title to be Confirmed.
Jan Lötvall, Professor, University of Gothenburg; Founding President of ISEV; Editor-in-Chief, Journal of Extracellular Vesicles, Sweden

00:00

Innovative Therapeutics Development Using BioDrone® Platform Technology
ShinGyu Bae, CEO, MDimune Inc., Korea South

MDimune Inc. was founded in 2015 to bring hope to many suffering patients by enabling more efficient drug delivery. Our innovative therapeutics platform called the “BioDrone® Technology” leverages the cell-derived vesicles (CDVs) obtained from various human cells to achieve target-specific drug delivery. Using BioDrone® Technology platform, we are striving to move forward the drug development endeavors against diverse challenges in human health.

Exosomes have emerged as one of the most promising therapeutics in the last decade and are actively pursued to address diverse disease areas including cancer and regenerative medicine. Despite their therapeutic potentials, a small quantity of naturally released exosomes and subsequent purification steps have hindered broader application of exosomes. The BioDrone® Technology recently developed by MDimune drastically improved the yield by producing CDVs using a proprietary extrusion method. Using this innovative technology, researchers can also deliver CDVs loaded with drugs to the specific target (e.g., lesion) more efficiently, which mimics a “drone” that has revolutionized the logistics industry. This technique is a new concept of drug delivery platform technology that can significantly reduce the adverse effects as well as maximize the therapeutic efficacy with a small amount of drug. Recently, the research and development of stem cell-based regenerative medicine has continually expanded, and the efficacy of stem cell-derived exosomes has gained broad attraction. We demonstrated the regenerative potentials of BioDroneTM Technology in multiple disease models. CDVs derived from stem cells enhanced the survival of the alveoli in chronic obstructive pulmonary disease (COPD) animal model. CDVs also alleviated the pain and promoted cartilage regeneration in the osteoarthritis (OA) animal model. Furthermore, CDVs have regenerative potential for damaged neurons as demonstrated in vitro in the neurodegenerative disease models such as Alzheimer's disease and Parkinson's disease. Currently, MDimune is striving to expand partnerships with biotech, pharmaceutical companies and hospitals to develop innovative therapies based on BioDrone® Technology.

00:00

Steve SoperKeynote Presentation

Identification of Different Subpopulations of Circulating Tumor Cells in the Blood of Localized and Metastatic Cancer Patients Using Microfluidics
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

Liquid biopsies are becoming an attractive source of biomarkers that can be used to manage a variety of cancer-related diseases. One of the principle biomarkers for oncology-related diseases found in blood is circulating tumor cells (CTCs). The challenge associated with using CTCs as biomarkers for many cancer-related diseases has been the modest clinical sensitivity demonstrated using the FDA-approved platform. CTCs expressing invasive phenotypes down-regulate epithelial antigens, such as the epithelial cell adhesion molecule – EpCAM, which is typically used for the affinity selection of CTCs. As such, CTCs may have a continuum of phenotypes and thus, a single selection marker may not address all cells comprising the tumor microenvironment. We have developed a CTC selection strategy that employs two polymeric microfluidic chips modified with antibodies and connected in series with each selecting a distinct CTC subpopulation from a single blood sample. In addition to the common marker used for CTC positive selection (EpCAM), Fibroblast Activation Protein alpha (FAPa) expressing CTCs can also be selected. Using the dual selection strategy, both CTC types were detected from patients with clinical sensitivity that showed significant improvement compared to selection in which only EpCAM was used. Approximately 90% of the selected CTCs were found not to co-express both antigens. Due to the high purity (>80%) and clinical yields (>95% recovery) of the dual selection strategy, molecular analysis of both EpCAM and FAP-alpha CTCs could be carried out including next generation sequencing, and droplet digital PCR. Our results suggest FAP-alpha and EpCAM CTCs can be used in concert to guide therapeutic decisions for cancer patients. In this presentation, I will discuss the microfluidic chips we use for the selection of CTCs, the clinical results secured using these chips, and the molecular profiling of both CTC subpopulations.

00:00

Multifluorescence NTA - Next Generation EV Characterization with Particle Metrix ZetaView
Sven Rudolf Kreutel, General Sales Manager, Particle Metrix GmbH, Germany

Nanoparticle Tracking Analysis (NTA) has emerged to a vital and fast characterization technology for exosomes, microvesicles or viruses. In combination with fluorescence detection (F-NTA), NTA enables the user to perform biomarker detection on the single particle level, thus enhancing real EV concentration measurements. Classic NTA instruments however are equipped with one laser, requiring phenotyping in sequence. Here we report the multi-fluorescence detection of four independent biomarkers (CD63, CD81, CD9 and CD41) in one NTA sample with the new Particle Metrix ZetaView QUATT for the first time.

00:00

Andreas MöllerKeynote Presentation

Protein Content of Extracellular Vesicles as Biomarker in Cancer
Andreas Möller, Associate Professor, QIMR Berghofer Medical Research Institute, Australia

Despite significant therapeutic advances, cancer remains a leading cause of death worldwide. A significant clinical problem is the generally late discovery of a cancer and the uncertainty of choosing the most effective therapy for the individual patient. Several novel biomarkers are proposed, ranging from genetic and genomic evaluations of the cancer or the cancer material in circulation to assessing nucleic acids, proteins or lipids. Accurate cancer biomarkers, in particular non-invasive liquid biomarkers based on blood samples or other body fluids, will allow clinicians to identify cancer patients early, triage them to the most appropriate intervention and follow the response of the cancer in real time over the course of the therapy.

In this presentation, I will share data on a novel biomarker for Non-Small-Cell Lung Cancer (NSCLC). We have developed a blood-based multi-protein signature capable of accurately prognosticating clinical outcome in NSCLC patient cohorts. This signature is contained in small circulating nano-vesicles termed exosomes. Overall, this work describes a novel prognostic biomarker signature to identify early stage NSCLC patients at risk of developing metastatic NSCLC, thereby enabling implementation of personalized adjuvant treatment decisions.


Agenda is not currently available
Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com